Mochida Pharmaceutical announced that it had signed a sales partnership agreement in the U.S. for ReFeel, a nerve regeneration guidance material. The signing of the agreement was announced in a timely disclosure, and future developments are expected to draw attention.
Mochida Pharmaceutical announced that it had signed a sales partnership agreement in the U.S. for ReFeel, a nerve regeneration guidance material. The announcement was made as timely disclosure information.
The counterparty and detailed terms of the agreement were not provided in the release. The publicly disclosed information focuses on the signing of the agreement and the expansion into the region.
ReFeel is a medical material targeting the field of nerve regeneration, and the U.S. sales partnership could strengthen the supply framework in the local market.
Nikkei-affiliated news organizations and related websites reported the development, conveying facts based on the timely disclosure information.